PLRX (Pliant Therapeutics Inc) vs S&P 500 Comparison

PLRX

S&P 500

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap Between PLRX and GSPC

Show

PLRX

S&P 500

Add Stock

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

S&P 500

PLRX

JEF

JNJ

4312

Add Stock

1Y 3Y 5Y 10Y 15Y 20Y

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Pliant Therapeutics Inc
Glance View

Market Cap

78.3m USD

Industry

Pharmaceuticals

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 91 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. The company focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.

View PLRX Analysis

PLRX Intrinsic Value

Show

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

PLRX

vs

S&P 500

Stocks Performance
PLRX vs S&P 500

Performance Gap
PLRX vs S&P 500

Performance By Year
PLRX vs S&P 500

Competitors Performance
Pliant Therapeutics Inc vs Peers

Pliant Therapeutics Inc
Glance View

Company

Help

Tools

Stocks

PLRX vs S&P 500

Stocks Performance PLRX vs S&P 500

Performance Gap PLRX vs S&P 500

Performance By Year PLRX vs S&P 500

Competitors Performance Pliant Therapeutics Inc vs Peers

Pliant Therapeutics Inc Glance View

Company

Help

Tools

Stocks

PLRX

vs

S&P 500

Stocks Performance
PLRX vs S&P 500

Performance Gap
PLRX vs S&P 500

Performance By Year
PLRX vs S&P 500

Competitors Performance
Pliant Therapeutics Inc vs Peers

Pliant Therapeutics Inc
Glance View